Eton Pharmaceuticals, Inc. (ETON)

NASDAQ: ETON · USD

$51.7

+0.56 (+1.1%)· Recorded snapshot

Market cap	1.5B
Revenue (ttm)	105.6M
Net income (ttm)	12.7M
EPS (ttm)	$0.43
Shares out	28.6M
P/E (trailing)	120.8x
P/E (forward)	35.2x
Volume	256,302
Beta	0.90

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 105.6M
Net income (ttm): 12.7M
EPS (ttm): $0.43
P/E (trailing): 120.8x
P/E (forward): 35.2x
Market cap: 1.5B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ถือ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E35.2

P25 n/aP50 n/aP75 n/a

Trailing P/E120.8

P25 n/aP50 n/aP75 n/a

ROE36

P25 n/aP50 n/aP75 n/a

ROIC45

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ETON indicators

Market & fundamental data

Available fields

244

Groups with data

Currency

USD

Showing 244 of 244 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001710340
Company name	Eton Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	29772L108
Earnings date	2026-11-09
Earnings time	amc
Employees	44
Employees change	13
Employees growth	41.94%
Enterprise value	$1.5B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2017
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2018-11-13
Is primary listing	Yes
Is SPAC	No
ISIN number	US29772L1089
Last 10-K release date	2026-03-19
Last earnings date	2026-08-13
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$1.5B
Market cap category	Small-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$51.72
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ETON
U.S. state	Illinois
Website	https://www.etonpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	64.65x
Earnings yield	0.83%
EV/Earnings	115.96x
EV/EBIT	71.3x
EV/EBITDA	58.43x
EV/FCF	99.87x
EV/Sales	13.93x
FCF / EV yield	1%
FCF yield	1%
Forward EV/Sales	7.61x
Forward P/E	35.18x
Forward P/S	7.6x
Graham number	3.98223
Graham upside	-92.25%
Industry forward P/E	13.87x
Industry P/E	173.94x
P/(FCF - SBC) ratio	154.13x
P/(OCF - SBC) ratio	147.88x
P/B ratio	31.07x
P/E ratio	120.84x
P/FCF ratio	99.71x
P/OCF ratio	97.05x
P/S ratio	13.91x
Price / tangible book value	1,619.5x
Price/EBITDA ratio	58.34x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	19.54%
EBITDA margin	23.84%
Effective tax rate	0.49%
FCF margin	13.95%
Gross margin	61.41%
Operating margin	19.54%
Pretax margin	12.08%
Profit margin	12.02%
Profit per employee	$288,364
Profitable quarters	3
Revenue per employee	$2.4M
ROA	11.86%
ROA (5Y)	-4.94%
ROCE	29.19%
ROE	35.97%
ROE (5Y)	-22.88%
ROIC	45.04%
SBC / revenue	4.93%
Tax / revenue	0.06%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth (QoQ)	600%
EPS growth quarters	3
EPS growth years	0
FCF growth	20.52%
FCF growth (Q)	-8.78%
FCF growth (QoQ)	-0.95%
FCF growth 3Y	30.17%
Gross profit growth	75.68%
Gross profit growth (Q)	98.48%
Gross profit growth 3Y	44.7%
Gross profit growth 5Y	38.06%
Net income growth (QoQ)	645.05%
Net income growth quarters	3
Net income growth years	0
OCF growth	23.69%
OCF growth (Q)	-8.85%
OCF growth (QoQ)	-2.03%
OCF growth 3Y	31.26%
Operating income growth	954.42%
Revenue growth	81.49%
Revenue growth (Q)	98.59%
Revenue growth (QoQ)	54.9%
Revenue growth 3Y	53.81%
Revenue growth 5Y	47.97%
Revenue growth quarters	8
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-403,000
Depreciation and amortization	$4.5M
EBIT	$20.6M
EBITDA	$25.2M
EPS	$0.43
FCF per share	$0.52
Financing cash flow	$1.7M
Free cash flow	$14.7M
Free cash flow minus SBC	$9.5M
Gross profit	$64.8M
Income taxes	$63,000
Investing cash flow	$-15.4M
Net borrowing	$-3M
Net cash flow	$1.5M
Net income	$12.7M
Operating cash flow minus SBC	$9.9M
Operating income	$20.6M
Revenue	$105.6M
Stock-based compensation	$5.2M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	5.28
Book value per share	$1.65
Debt / EBITDA	1.15
Debt / equity	0.63
Debt / FCF	1.98
Interest coverage	4.52
Long-term assets	$47.2M
Long-term liabilities	$24.1M
Net cash (debt)	$-2.4M
Net cash / market cap	-0.16%
Net debt / EBITDA	0.09
Net debt / equity	0.05
Net debt / FCF	0.16
Piotroski F-Score	6
Property, plant and equipment	$1.5M
Shareholders' equity	$46.6M
Tangible book value	$907,000
Tangible book value per share	$0.03
Total assets	$115.8M
Total cash	$26.8M
Total debt	$29.2M
Total liabilities	$69.2M
WACC	9.32%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.97
Current assets	$68.6M
Current liabilities	$45.1M
Current ratio	1.52
Inventory turnover	2.4
Net working capital	$5.7M
Quick ratio	1.15
Working capital	$23.5M
Working capital turnover	3.96

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-11.94%
Dividend yield	0%
Shareholder yield	-11.94%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$41.38
1D price change	1.09%
1M price change	-10.56%
1M total return	-10.56%
1W price change	2.79%
1W total return	2.79%
1Y price change	179.17%
1Y return CAGR	179.36%
1Y total return	179.17%
20-day SMA	$52.37
200-day SMA	$35.33
3M price change	21.93%
3M total return	21.93%
3Y price change	1,279.41%
3Y return CAGR	139.78%
3Y total return	1,279.41%
50-day SMA	$56.31
50-day SMA vs 200-day SMA	50over200
52-week high	$66.37
52-week high date	2026-08-24
52-week low	$14.27
52-week low date	2026-02-05
5Y price change	816.34%
5Y return CAGR	55.75%
5Y total return	816.34%
6M price change	120%
6M total return	120%
All-time high	$66.37
All-time high date	2026-08-24
All-time low	$1.95
All-time low date	2022-09-23
Average true range (ATR)	$2.62
Average volume	473K
Beta (1Y)	-0.39
Beta (2Y)	0.58
Beta (5Y)	0.9
Change from 52-week high	-22.07%
Change from 52-week low	262.44%
Change from all-time high	-22.27%
Change from all-time low	2,545.64%
Change from open	1.09%
Day's gap	0%
Dollar volume	$13.3M
High price	$51.94
Low price	$51.16
Monthly RSI	73.84
Open price	$51.16
Position in 52-week range	71.79%
Premarket change	0.86%
Premarket close	$51.16
Premarket price	$51.60
Previous close	$51.16
Price vs 150-day SMA	24.66%
Price vs 20-day SMA	-1.48%
Price vs 200-day SMA	46.01%
Price vs 50-day SMA	-8.38%
Relative volume	0.54
RSI	45.54
Sharpe ratio	1.72
Sharpe ratio (3Y)	1.6
Sharpe ratio (5Y)	0.94
Sortino ratio	3.66
Sortino ratio (3Y)	2.92
Sortino ratio (5Y)	1.66
Volume	256.3K
Weekly RSI	60.61
YTD price change	205.09%
YTD total return	205.09%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	22.3M
Float percentage	78.01%
Shares change (QoQ)	3.93%
Shares change (YoY)	11.94%
Shares held by insiders	4.93%
Shares held by institutions	54.45%
Shares outstanding	28.6M
Short % of float	8.72%
Short % of shares	6.8%
Short ratio	3.3 days

Deeper analysis on ETON

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ETON report

Is a complete ETON research report available?

No complete published report is available for Eton Pharmaceuticals, Inc. (ETON) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Eton Pharmaceuticals, Inc. (ETON)

Price

Financial snapshot

Fair-value bridge

Latest news · ETON

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ETON indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ETON

Frequently asked questions